Poor
Not Aligned
Patient Risk:
Moderate
Summary
The content provided does not contain an AI-generated response to the FDA label question; instead it includes a mixture of user claims, an asserted label assessment, and metadata about sections. Because the actual AI response text is not present for evaluation against the supplied prescribing information, alignment cannot be verified and is treated as largely unsupported.
Category Scores
Accurate Statements
Lenalidomide (REVLIMID) embryo-fetal toxicity with pregnancy contraindication, including that females must avoid pregnancy for at least 4 weeks before and after therapy, and use contraception with pregnancy testing (as described).
Supported by provided label excerpts: Contraindications (4.1), Embryo-Fetal Toxicity (5.1), Pregnancy risk summary (8.1), and Medication Guide embryo-fetal toxicity counseling; REMS availability described in 5.2.
REVLIMID causes hematologic toxicity (neutropenia and thrombocytopenia) and requires CBC monitoring.
Supported by provided label excerpts: Hematologic Toxicity (5.3) and Medication Guide hematologic toxicity counseling.
REVLIMID increases venous and arterial thromboembolism risk (DVT/PE; MI/stroke) and thromboprophylaxis is recommended.
Supported by provided label excerpts: Venous and Arterial Thromboembolism (5.4) and Medication Guide venous/arterial thrombosis counseling.
Unsupported Statements
“The excerpts provided are consistent with the REVLIMID Prescribing Information (capsules), including the boxed warning language and Medication Guide revisions (e.g., ‘Revised: MAR 2023’ shown in the text you included).”
The provided prompt does not include the actual AI response making this claim; and the prompt’s content does not provide the actual referenced label text verifying the specific revision date (MAR 2023). This cannot be confirmed from the supplied information.
“FDA exclusivity dates for Revlimid depend on which specific FDA approval or supplement/indication is being considered… [multiple exclusivity-related assertions]”
No prescribing information content about FDA exclusivity dates/timelines was supplied in the label excerpts provided. These statements are therefore unsupported by the supplied prescribing information.
“The most direct way to find the exact Revlimid exclusivity end date… look up Revlimid’s FDA exclusivity listing…” and “DrugPatentWatch.com is a common starting point…”
The supplied prescribing information excerpts do not include FDA exclusivity listings, exclusivity end dates, or third-party tracking resources. Unsupported by the label information provided.
Contradictions
Low
AI Statement
None identified.
Label Reference
Important Omissions
The actual AI-generated response text that is supposed to be evaluated against the label is not provided separately. Instead, the prompt includes a large block of user claims and an asserted assessment. Without the exact AI response content, a precise label-by-label alignment review is not possible.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Part of the provided content aligns with the supplied label excerpts (major boxed warning topics). However, numerous exclusivity-related statements are unsupported by prescribing information, and the absence of the actual AI response text prevents confirmation of what was claimed and whether any additional clinically relevant claims were made.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Evaluation target is unclear: the prompt does not provide the actual AI-generated response to be checked against the label; additionally, several claims concern FDA exclusivity timelines which are not present in the supplied prescribing information excerpts.
Suggested Improvement
Provide the exact AI response text to be audited, and restrict the evaluation to claims directly supported/unsupported/contradicted by the provided REVLIMID prescribing information excerpts.